Glibenclamide, a sulfonylurea derivative, is used primarily as an oral antidiabetic agent in patients with DM type 2 and gestational diabetes due to its ability to stimulate insulin secretion in pancreatic β-cells [46,47]. This evidence concerns the gene INS and gestational diabetes.